No abstract available
Keywords:
Bypass track resistance; Cutaneous eruption; Lung adenocarcinoma; Oncogenic driver mutations; ROS1 tyrosine kinase inhibitor.
MeSH terms
-
Carcinoma, Non-Small-Cell Lung* / drug therapy
-
Carcinoma, Non-Small-Cell Lung* / genetics
-
Carcinoma, Non-Small-Cell Lung* / pathology
-
Female
-
Humans
-
Lung Neoplasms* / genetics
-
Lung Neoplasms* / pathology
-
Male
-
Middle Aged
-
Mutation* / genetics
-
Protein-Tyrosine Kinases* / genetics
-
Proto-Oncogene Proteins B-raf* / genetics
-
Proto-Oncogene Proteins* / genetics
-
Skin Neoplasms* / genetics
-
Skin Neoplasms* / pathology
Substances
-
Proto-Oncogene Proteins B-raf
-
ROS1 protein, human
-
BRAF protein, human
-
Proto-Oncogene Proteins
-
Protein-Tyrosine Kinases